Cargando…
Interaction of Ras Binding Domain (RBD) by chemotherapeutic zinc oxide nanoparticles: Progress towards RAS pathway protein interference
Zinc oxide (ZnO) NP is considered as a nanoscale chemotherapeutic. Thus, the drug delivery of this inorganic NP is of considerable importance. Ras mutations are common in cancer and the activation of this signaling pathway is a hallmark in carcinoma, melanoma and many other aggressive malignancies....
Autores principales: | Mathew, Elza Neelima, Hurst, Miranda N., Wang, Baolin, Murthy, Vaibhav, Zhang, Yuntao, DeLong, Robert K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7744048/ https://www.ncbi.nlm.nih.gov/pubmed/33326476 http://dx.doi.org/10.1371/journal.pone.0243802 |
Ejemplares similares
-
Graded inhibition of oncogenic Ras-signaling by multivalent Ras-binding domains
por: Augsten, Martin, et al.
Publicado: (2014) -
KRAS interaction with RAF1 RAS-binding domain and cysteine-rich domain provides insights into RAS-mediated RAF activation
por: Tran, Timothy H., et al.
Publicado: (2021) -
Targeting Ras-binding domain of ELMO1 by computational nanobody design
por: Tam, Chunlai, et al.
Publicado: (2023) -
CREBBP knockdown enhances RAS/RAF/MEK/ERK signaling in Ras pathway mutated acute lymphoblastic leukemia but does not modulate chemotherapeutic response
por: Dixon, Zach A., et al.
Publicado: (2017) -
VPS35 binds farnesylated N-Ras in the cytosol to regulate N-Ras trafficking
por: Zhou, Mo, et al.
Publicado: (2016)